Re-exposure to heparin in uremic patients requiring hemodialysis with heparin-induced thrombocytopenia.
Wanaka
K
K
Matsuo
T
T
Matsuo
M
M
Kaneko
C
C
Miyashita
K
K
Asada
R
R
Matsushima
H
H
Nakajima
Y
Y
D000368:Aged; D000369:Aged, 80 and over; D000906:Antibodies / Q000097:blood; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology; D004334:Drug Administration Schedule; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006493:Heparin / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000628:therapy*; D008297:Male; D010974:Platelet Aggregation / Q000187:drug effects; D010978:Platelet Factor 4 / Q000276:immunology; D011237:Predictive Value of Tests; D006435:Renal Dialysis / Q000009:adverse effects*; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000276:immunology / Q000628:therapy; D013927:Thrombosis / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D013997:Time Factors; D014511:Uremia / Q000097:blood / Q000188:drug therapy*
D000906:Antibodies; D000925:Anticoagulants; D010978:Platelet Factor 4; D006493:Heparin